| Q95359130 | Q95359130 |
| Q95359135 | Q95359135 |
| Q33418663 | 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. |
| Q48016870 | A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia |
| Q90386505 | A case of acute myocardial infarction during perioperative period of non-cardiac surgery in a patient with antiphospholipid syndrome and a history of coronary artery bypass surgery |
| Q47924655 | A case of antiphospholipid syndrome presenting with pulmonary truncus and main pulmonary artery thrombosis |
| Q43095400 | A case of antiphospholipid syndrome refractory to secondary anticoagulating prophylaxis after deep vein thrombosis-pulmonary embolism |
| Q90378053 | A case of coronary artery disease with antiphospholipid syndrome that showed repeated stent thrombosis |
| Q53911676 | A case of recurrent stroke due to late onset antiphospholipid syndrome. |
| Q55279180 | A importância de reconhecer a síndrome antifosfolípide na medicina vascular. |
| Q33379963 | A new diagnostic approach to better identify antiphospholipid syndrome |
| Q25255895 | A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli |
| Q35627251 | A rare presentation of primary antiphospholipid syndrome |
| Q43654143 | A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan |
| Q38394256 | A rheumatology perspective on cutaneous vasculitis: assessment and investigation for the non-rheumatologist. |
| Q83450164 | A spontaneous intercostal artery hemorrhage in systemic lupus erythematosus |
| Q41666889 | A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? |
| Q96306532 | ADRENAL INSUFFICIENCY SECONDARY TO BILATERAL ADRENAL HEMORRHAGE ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME |
| Q33196667 | APS and the brain |
| Q51846266 | Acquired Thrombophilia. |
| Q33373539 | Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease |
| Q33396280 | Acquired immune-mediated thrombophilia in lymphoproliferative disorders |
| Q92267125 | Acute Myocardial Infarction Involving Left Main Artery in a Patient with Antiphospholipid Syndrome |
| Q33403443 | Acute adrenal failure as the presenting feature of primary antiphospholipid syndrome in a child |
| Q37314619 | Acute adrenal insufficiency due to primary antiphospholipid antibody syndrome |
| Q90243715 | Acute coronary syndrome leading to revision of a co-morbid condition in a young man with arthritis |
| Q36490337 | Acute manifestations of autoimmune connective tissue diseases |
| Q90377963 | Acute myocardial infarction due to antiphospholipid antibody syndrome in a young pregnant woman |
| Q92912330 | Acute myocardial infarction in a young man with large left ventricular thrombus and the antiphospholipid syndrome |
| Q35444451 | Acute myocardial infarction in young adults with antiphospholipid syndrome: report of two cases and literature review |
| Q37788783 | Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. |
| Q38876334 | Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review |
| Q64097620 | Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome |
| Q36951011 | Advances in lupus and Sjögren's syndrome: a tribute to Josep Font |
| Q41824978 | All that seems sepsis is not sepsis |
| Q91792514 | Alveolar Hemorrhage, a Rare and Life-Threatening Complication of Catastrophic Antiphospholipid Syndrome |
| Q50632129 | An Algorithmic Approach to Management of Venous Thromboembolism. |
| Q64996302 | An Unusual Case of Antiphospholipid Syndrome Presenting as Chorea. |
| Q46110307 | An unusual cause of hemichorea-hemiballism in a patient with systemic lupus erythematosus. |
| Q43901099 | Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients |
| Q33372650 | Anesthetic implications of the catastrophic antiphospholipid syndrome |
| Q59130718 | Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS) |
| Q40396553 | Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. |
| Q39094833 | Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature |
| Q96689838 | Antibodies to cellular prion protein and its cognate ligand stress-inducible protein 1 in systemic lupus erythematosus |
| Q46796993 | Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome |
| Q36086136 | Anticardiolipin and anti-beta-2-glycoprotein I antibodies |
| Q50524471 | Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. |
| Q35934717 | Antiphospholipid (Hughes) syndrome |
| Q46049160 | Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. |
| Q36060060 | Antiphospholipid Antibodies in Lupus Nephritis |
| Q73245534 | Antiphospholipid Antibody Syndrome |
| Q37640945 | Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study |
| Q90312460 | Antiphospholipid Syndrome and Kidney Involvement: New Insights |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q35756040 | Antiphospholipid Syndrome during pregnancy: the state of the art |
| Q33768066 | Antiphospholipid Syndrome: Multiple Manifestations in a Single Patient-A High Suspicion Is Still Needed |
| Q37318783 | Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome |
| Q42167437 | Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis |
| Q48159962 | Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus |
| Q43626449 | Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. |
| Q48443751 | Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome |
| Q33379770 | Antiphospholipid antibodies in adults with immune thrombocytopenic purpura |
| Q86552138 | Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India |
| Q44281373 | Antiphospholipid antibodies in patients with purported 'chronic Lyme disease'. |
| Q36305607 | Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis |
| Q73628348 | Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection |
| Q36915667 | Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome |
| Q28192380 | Antiphospholipid antibodies in young adults with stroke |
| Q37409260 | Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway |
| Q53279549 | Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. |
| Q40337946 | Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis |
| Q36799474 | Antiphospholipid antibodies: laboratory and pathogenetic aspects |
| Q88528041 | Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome |
| Q99712595 | Antiphospholipid antibody syndrome with thrombotic splenic infarcts associated with acute cytomegalovirus infection |
| Q61809546 | Antiphospholipid immune complexes as thrombosis risk marker |
| Q28195585 | Antiphospholipid syndrome |
| Q30235423 | Antiphospholipid syndrome |
| Q64046338 | Antiphospholipid syndrome |
| Q83008761 | Antiphospholipid syndrome |
| Q55891386 | Antiphospholipid syndrome |
| Q91390119 | Antiphospholipid syndrome - an update |
| Q84623592 | Antiphospholipid syndrome and polyarteritis nodosa: a diagnostic and therapeutic challenge |
| Q46439459 | Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies |
| Q37045158 | Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview |
| Q33361734 | Antiphospholipid syndrome in Greece: clinical and immunological study and review of the literature |
| Q33375598 | Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients |
| Q51140007 | Antiphospholipid syndrome in Sarawak: real world experience in a developing country. |
| Q39612628 | Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. |
| Q35680777 | Antiphospholipid syndrome infectious origin |
| Q43167389 | Antiphospholipid syndrome is an important modifiable risk factor of stroke in the young. |
| Q38162724 | Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study |
| Q38596401 | Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review |
| Q37335950 | Antiphospholipid syndrome presenting as unilateral renal artery occlusion: case report and literature review |
| Q91642031 | Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations |
| Q35099505 | Antiphospholipid syndrome: an overview. |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q37729831 | Antiphospholipid syndrome: frequency, main causes and risk factors of mortality |
| Q36844544 | Antiphospholipid syndrome: laboratory testing and diagnostic strategies |
| Q82357870 | Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies |
| Q36337350 | Antiphospholipid-related chorea. |
| Q24185813 | Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome |
| Q24185949 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome |
| Q47884958 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. |
| Q33376794 | Are antiphospholipid antibodies an essential requirement for an effective immune response to infections? |
| Q41350748 | Arterial Embolisms and Thrombosis in Upper Extremity Ischemia |
| Q39502759 | Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis |
| Q85206714 | Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus |
| Q33421547 | Association of anti-phospholipid antibodies with connective tissue diseases |
| Q37826101 | Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review |
| Q36458127 | Atherogenesis in rheumatology |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q34467454 | Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I |
| Q35849691 | Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome |
| Q36436250 | Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. |
| Q37283009 | Autoimmune-mediated atherothrombosis |
| Q33440226 | Bilateral adrenal hemorrhage in the background of Escherichia coli sepsis: a case report |
| Q38615759 | Bilateral internal carotid artery occlusion associated with the antiphospholipid antibody syndrome |
| Q36881159 | Bilateral renal infarction in a lupus patient: an unusual pathology |
| Q36225236 | Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43 |
| Q34374916 | Bone infarcts in a woman with systemic lupus erythematosus and antiphospholipid antibody syndrome |
| Q28260452 | Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab |
| Q89415073 | Budd-Chiari syndrome has different presentations and disease severity during adolescence |
| Q45230040 | CAPS Registry |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q53758664 | Catastrophic Antiphospholipid Syndrome. |
| Q41244904 | Catastrophic antiphospholipid antibody syndrome in a child with thrombotic microangiopathy |
| Q47555812 | Catastrophic antiphospholipid lung syndrome in young female with repeated abortions |
| Q73927246 | Catastrophic antiphospholipid syndrome |
| Q45912780 | Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. |
| Q36729464 | Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature). |
| Q35953379 | Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases |
| Q81412262 | Catastrophic antiphospholipid syndrome in a 14-year-old child |
| Q37077038 | Catastrophic antiphospholipid syndrome in childhood: presentation with an inferior caval vein mass |
| Q38792177 | Catastrophic antiphospholipid syndrome in pregnancy, a diagnosis that should not be missed |
| Q51756848 | Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction. |
| Q44700183 | Catastrophic antiphospholipid syndrome presenting with multiorgan failure and gangrenous lesions of the skin |
| Q41870499 | Catastrophic antiphospholipid syndrome presenting with sudden renal failure: The lesson lies in vascular lesions |
| Q22255576 | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines |
| Q36951067 | Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font |
| Q37339827 | Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse |
| Q38154328 | Catastrophic wounds |
| Q33720414 | Central nervous system involvement in systemic diseases: Spectrum of MRI findings |
| Q28196276 | Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers |
| Q34684028 | Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome |
| Q61914430 | Chapter 8 Systemic Manifestations of the Antiphospholipid Syndrome |
| Q33379920 | Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. |
| Q33396957 | Chorea in primary antiphospholipid syndrome is associated with rheumatic fever |
| Q53552867 | Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls. |
| Q93163118 | Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome |
| Q60949185 | Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome |
| Q38657043 | Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers |
| Q33376802 | Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies |
| Q38994352 | Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort |
| Q47685633 | Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients |
| Q43633055 | Clinical characteristics of stroke patients with antiphospholipid antibodies |
| Q42339925 | Clinical manifestations of the anti-phospholipid syndrome as defined by the updated Sapporo classification criteria |
| Q28222458 | Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up |
| Q34014540 | Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review |
| Q33365787 | Clinicohematologic spectrum in patients with lupus anticoagulant. |
| Q35554870 | Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome |
| Q33374901 | Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis |
| Q90468632 | Co-existing Bilateral Pulmonary Embolism and Intra-cardiac Mass: A Case of Catastrophic Antiphospholipid Syndrome-like Disease |
| Q49793897 | Coexistence of antiphospholipid antibodies and cephalalgia. |
| Q37963790 | Cognitive dysfunction and antiphospholipid antibodies |
| Q50702607 | Cognitive impairment and antiphospholipid syndrome: is paradoxical embolism the rule? |
| Q53399109 | Common femoral artery disease in antiphospholipid syndrome: histopathology. |
| Q33415519 | Complement the hemostatic system: an intimate relationship |
| Q37107689 | Connective tissue: Vascular and hematological (blood) support |
| Q37976385 | Coronary heart disease in young adults |
| Q35953555 | Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? |
| Q37625571 | Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus |
| Q64075728 | Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome |
| Q64026078 | Cryptogenic Stroke—The Appropriate Diagnostic Evaluation |
| Q57059278 | Curative resolution of chronic thromboembolic pulmonary hypertension with pulmonary thromboendarterectomy in primary antiphospholipid syndrome: A case report |
| Q37642830 | Current management of antiphospholipid syndrome-related thrombosis |
| Q35181703 | Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q39793593 | Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases |
| Q53591721 | Cutaneous pseudovasculitis, antiphospholipid syndrome and obstetric misadventure. |
| Q37853050 | Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome |
| Q36947358 | D-dimer level and the risk for thrombosis in systemic lupus erythematosus |
| Q42955444 | De novo infantile primary antiphospholipid antibody syndrome |
| Q80470542 | Delayed catastrophic antiphospholipid syndrome after massive cerebral infarction |
| Q24678418 | Demyelination in rheumatic diseases |
| Q37778646 | Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome |
| Q59133704 | Detection of annexin A8 antibodies in serum of patients with antiphospholipid syndrome |
| Q37011051 | Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome |
| Q48046065 | Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). |
| Q35954573 | Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. |
| Q38366484 | Diabetes and epilepsy in children and adolescents |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q36577371 | Diagnosis of antiphospholipid syndrome |
| Q45191182 | Diagnosis of the antiphospholipid syndrome in anticoagulated patients |
| Q41280109 | Differential assay reactivity of immunglobulin A anti-ß2 glycoprotein I antibodies: implications for the clinical interpretation of antiphospholipid antibody testing |
| Q33421814 | Difficult clinical situations in the antiphospholipid syndrome |
| Q61974452 | Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus? |
| Q26771128 | Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases? |
| Q38089684 | Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? |
| Q33731711 | EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome |
| Q57059420 | Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report |
| Q33967600 | Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. |
| Q60918207 | Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome |
| Q39264755 | Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation |
| Q39586997 | Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome |
| Q35625233 | Endothelium and the brain in CNS lupus |
| Q35116961 | Epidemiology and etiology of young stroke |
| Q89588653 | Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study |
| Q89002090 | Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism |
| Q35555112 | Ethnic and geographical variation in antiphospholipid (Hughes) syndrome |
| Q44428099 | Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients |
| Q37283017 | Examining the non-linear relationship between monoclonal antiphospholipid antibody sequence, structure and function |
| Q39062931 | Exhausting multiple hemodialysis access failures |
| Q34169570 | Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). |
| Q37327054 | Familial primary antiphospholipid syndrome: A report of co-occurrence in three Malaysian family members |
| Q47208773 | Frequency of psychological alterations in primary antiphospholipid syndrome: preliminary study |
| Q36283452 | From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link? |
| Q39945387 | Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients |
| Q37107525 | Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. |
| Q93339908 | Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils |
| Q37982121 | Guidelines on the investigation and management of antiphospholipid syndrome |
| Q33937755 | Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease |
| Q36842443 | Heart failure with complete recovery in a patient with systemic lupus erythematosus |
| Q36596375 | Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus |
| Q33411323 | Hematological disorders in patients with systemic lupus erythematosus |
| Q36765838 | Hepatic manifestations in hematological disorders |
| Q36009039 | High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature |
| Q33410017 | High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies |
| Q40334297 | Histopathological analysis of cerebral hemorrhage in systemic lupus erythematosus complicated with antiphospholipid syndrome |
| Q46115743 | Hospital based prospective longitudinal clinical and immunologic study of 179 patients of primary anti-phospholipid syndrome |
| Q31101744 | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? |
| Q38261156 | Hughes syndrome and multiple sclerosis. |
| Q36326309 | Human parvovirus B19 infection and antiphospholipid-syndrome: the two sides of one medal? |
| Q33363684 | Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients |
| Q35918396 | IVIG in APS pregnancy |
| Q28210517 | IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome |
| Q46715633 | Ictus and antiphospholipid syndrome: how much is enough? |
| Q90115791 | Idiopathic Normal Pressure Hydrocephalus - What We Know |
| Q81247239 | IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein i antibodies reflect different forms of recent thrombo-embolic events |
| Q51835838 | Immune-Mediated Heart Disease. |
| Q90043733 | Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome |
| Q37316712 | Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis |
| Q35419865 | Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. |
| Q48041183 | Impairment of quality of life in patients with antiphospholipid syndrome |
| Q39328138 | In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis |
| Q38591312 | Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. |
| Q35625927 | Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay |
| Q37224652 | Increased anti-phospholipid antibodies in autism spectrum disorders |
| Q36339540 | Infectious origin of the antiphospholipid syndrome |
| Q45771233 | Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study |
| Q38125276 | Inherited and acquired thrombophilias |
| Q37585221 | Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome |
| Q94562624 | Intensive Care Society State of the Art 2018 Abstracts |
| Q36387401 | Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis |
| Q43015923 | Internal medical investigations for non-arteritic retinal artery occlusion |
| Q44805019 | Intracardiac thrombosis complicating antiphospholipid antibody syndrome |
| Q28175909 | Intracerebral hemorrhage in a patient with SLE and catastrophic antiphospholipid syndrome (CAPS): report of a case |
| Q35185887 | Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus |
| Q58604686 | Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women |
| Q40958953 | Intravascular Images of Coronary Stenosis with Multiple Channels in a Patient with Antiphospholipid Syndrome: The Optical Coherence Tomography Findings |
| Q33369796 | Intravenous immunoglobulin therapy in antiphospholipid syndrome |
| Q52884718 | Is leukocyte tissue factor the key to venous thrombosis in antiphospholipid syndrome? |
| Q47716145 | Is there a link between mean platelet volume and thrombotic events in antiphospholipid syndrome? |
| Q37704874 | Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome |
| Q36458164 | Laboratory diagnosis and management challenges in the antiphospholipid syndrome |
| Q35099172 | Laboratory diagnosis of the antiphospholipid syndrome |
| Q41790742 | Large scale evidence and replication: insights from rheumatology and beyond |
| Q33363576 | Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome |
| Q44943140 | Livedo racemosa and digital necrosis in a patient with primary seronegative antiphospholipid syndrome and fibromuscular dysplasia of peripheral arteries |
| Q83348539 | Livedo reticularis and related disorders |
| Q33376910 | Livedo reticularis as a criterion for antiphospholipid syndrome |
| Q26779125 | Livedo reticularis: A review of the literature |
| Q33390983 | Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome? |
| Q36033553 | Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome |
| Q46339090 | Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention |
| Q46188376 | Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up |
| Q45006590 | Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis |
| Q55054592 | Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. |
| Q35553102 | Lupus nephritis: current issues |
| Q98181529 | Management of anticoagulant-refractory thrombotic antiphospholipid syndrome |
| Q57656275 | Management of antiphospholipid syndrome |
| Q45913321 | Management of phenytoin-induced gingival enlargement in a patient with antiphospholipid antibody syndrome: A rare case report. |
| Q33423034 | Management of the antiphospholipid syndrome |
| Q93060997 | Managing antiphospholipid syndrome in pregnancy |
| Q37270276 | Mania: psychiatric manifestations of the antiphospholipid syndrome |
| Q38259336 | Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies |
| Q52806708 | Maternal Thrombophilia and Recurrent Miscarriage - Is There Evidence That Heparin is Indicated as Prophylaxis against Recurrence? |
| Q53773313 | Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study. |
| Q37088895 | Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism |
| Q94154085 | Methotrexate treatment and mortality in rheumatoid arthritis |
| Q33382350 | Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome |
| Q58210773 | Migraine and Antiphospholipid Antibodies: No Association Found in Migraine-Discordant Monozygotic Twins |
| Q37156443 | Migraine and ischemic stroke: a debated question |
| Q33240072 | Migraine and stroke--why do we talk about it? |
| Q53250090 | Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. |
| Q37625583 | Molecular mimicry in systemic lupus erythematosus |
| Q38098473 | Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome |
| Q40003664 | Multiple thromboses in a patient with systemic lupus erythematosus after splenectomy. |
| Q38753531 | Musculoskeletal manifestations of the antiphospholipid syndrome |
| Q38927578 | Mycophenolate mofetil therapy for two cases of antiphospholipid antibody-associated chorea |
| Q80439553 | Nasal septal perforation and antiphospholipid syndrome (Hughes syndrome) |
| Q33363243 | Neonatal outcome in patients with rheumatic disease |
| Q33418245 | Neonatal outcome in pregnant patients with antiphospholipid syndrome |
| Q80335294 | Neurologic manifestations of the antiphospholipid syndrome |
| Q53096115 | Neurological presentations of the antiphospholipid syndrome: three illustrative cases. |
| Q37168035 | New developments in lupus-associated antiphospholipid syndrome |
| Q37481227 | New potential therapies for the treatment of antiphospholipid syndrome |
| Q34140319 | New therapeutic targets for the antiphospholipid syndrome |
| Q37339107 | Newborn illnesses caused by transplacental antibodies |
| Q90567970 | Nine-test panel has superior sensitivity to detect antiphospholipid antibody syndrome in patients with or without SLE |
| Q38753510 | Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. |
| Q55440072 | Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. |
| Q36283415 | Nonorgan specific autoantibodies and heart damage |
| Q58551653 | Obstetric antiphospholipid syndrome |
| Q26998188 | Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications |
| Q87623072 | Octopus in a fisherman's heart |
| Q64248332 | Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL) |
| Q38697342 | Organ Damage and Quality of Life in Antiphospholipid Syndrome. |
| Q33412248 | Outcomes of patients with antiphospholipid syndrome after pulmonary endarterectomy |
| Q75288435 | Ovarian vein thrombosis in the antiphospholipid syndrome |
| Q38095148 | Overview and assessment of risk factors for pulmonary embolism |
| Q49723590 | Painful recurrent leg ulcers |
| Q53609736 | Paroxysmal non-kinesigenic dyskinesia in antiphospholipid syndrome. |
| Q45344078 | Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome |
| Q84631323 | Pathogenetic potential of antiphospholipid antibodies |
| Q37721597 | Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome |
| Q35309024 | Pathophysiology of the antiphospholipid antibody syndrome |
| Q34287356 | Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome |
| Q81359675 | Pauci-immune glomerulonephritis associated with primary antiphospholipid syndrome |
| Q89986376 | Pediatric APS: State of the Art |
| Q41100232 | Pediatric antiphospholipid syndrome |
| Q91715407 | Pediatric antiphospholipid syndrome |
| Q47104714 | Pharmacologic Complement Inhibition in Clinical Transplantation. |
| Q34040405 | Population-level evidence for an autoimmune etiology of epilepsy |
| Q42984904 | Portal vein thrombosis in a patient with hepatitis C virus-related cirrhosis complicated with antiphospholipid syndrome |
| Q35428011 | Possible Effect of Extended Use of Hormonal Contraception on Increased Levels of Antiphospholipid Antibodies in Infertile Women |
| Q90261755 | Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge |
| Q46560169 | Post-surgical hemorrhagic infarction of the adrenal gland as the first clinical manifestation of antiphospholipid syndrome after 43 years of antibody-positivity |
| Q90115787 | Pregnancy Management in Women with Antiphospholidic Syndrome |
| Q38891094 | Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy. |
| Q37551634 | Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution |
| Q38175887 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? |
| Q48477588 | Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. |
| Q35172091 | Pregnancy outcome in systemic lupus erythematosus: good news for the new millennium |
| Q37851849 | Pregnancy outcomes in Japanese patients with SLE: retrospective review of 55 pregnancies at a university hospital |
| Q37107290 | Pregnancy outcomes of antiphospholipid syndrome: In a low resource South Asian setting |
| Q36458150 | Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome). |
| Q60954866 | Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria |
| Q35636529 | Prevalence of the antiphospholipid syndrome in primary systemic vasculitis |
| Q39027911 | Prevention of thrombosis in antiphospholipid syndrome |
| Q33427672 | Primary Adrenal Failure due to Antiphospholipid Syndrome |
| Q33419540 | Primary anti-phospholipid antibody syndrome causing recurrent venous thrombosis and thrombocytopenia in a patient with Addison's disease |
| Q33422007 | Primary antiphospholipid syndrome associated with pneumonia: a case report of a 16-year-old male patient |
| Q33378048 | Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients |
| Q52649404 | Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia. |
| Q41937059 | Primary antiphospholipid syndrome with and without Sneddon's syndrome |
| Q38392607 | Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review |
| Q36458145 | Primary systemic vasculitis: treatment of difficult cases |
| Q35940083 | Primary versus secondary antiphospholipid syndrome: is this lupus or not? |
| Q51768759 | Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. |
| Q51773681 | Psychiatric manifestations as a primary symptom in antiphospholipid syndrome. |
| Q38325716 | Pulmonary hypertension in antiphospholipid syndrome |
| Q36960901 | Pulmonary hypertension, antiphospholipid antibodies, and syndromes |
| Q35277303 | Pulmonary manifestations of systemic lupus erythematosus patients with and without antiphospholipid syndrome |
| Q35535795 | Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. |
| Q84897034 | Recurrent acute coronary events in a young adult |
| Q33361019 | Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation |
| Q41830826 | Recurrent stent thrombosis in a patient with antiphospholipid syndrome and dual anti-platelet therapy non-responsiveness. |
| Q55710004 | Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. |
| Q43196044 | Recurrent thrombotic events after catastrophic antiphopholipid syndrome |
| Q36234341 | Relation between migraine and stroke |
| Q86984388 | Renal involvement in antiphospholipid syndrome |
| Q87467570 | Renal involvement in antiphospholipid syndrome |
| Q38838855 | Renal involvement in primary antiphospholipid syndrome |
| Q33944778 | Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients |
| Q37339048 | Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. |
| Q28307709 | Renal manifestations of the antiphospholipid syndrome |
| Q38119553 | Reproduction and autoimmune disease: important translational implications from embryo-maternal interaction |
| Q57464055 | Reversible Cognitive Dysfunction in Elderly-onset Systemic Lupus Erythematosus, Successfully Treated with Aggressive Immunosuppressive Therapy |
| Q30701440 | Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature |
| Q37845609 | Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? |
| Q37704593 | Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage |
| Q38222239 | Rheumatological diseases and kidneys: a nephrologist's perspective |
| Q41930841 | Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. |
| Q88220801 | Rivaroxaban to treat thrombotic antiphospholipid syndrome |
| Q59354270 | Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant) |
| Q41584303 | Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome |
| Q34573328 | Role of investigating thrombophilic disorders in young stroke. |
| Q64959086 | Safety of retrievable inferior vena cava filters in patients with the antiphospholipid syndrome. |
| Q26775647 | Sarcoidosis and Antiphospholipid Syndrome: A Systematic Review of Cases |
| Q45878162 | Screening for lupus anticoagulants in patients treated with vitamin K antagonists |
| Q36369289 | Screening tests of reproductive immunology in systemic lupus erythematosus |
| Q39237507 | Segmental small bowel necrosis associated with antiphospholipid syndrome: a case report |
| Q35867162 | Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke |
| Q36510210 | Seminar on choreas |
| Q41657354 | Serologic false-positive reactions for syphilis in children of allergic purpura |
| Q37401677 | Serologic laboratory findings in malignancy |
| Q40435089 | Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab. |
| Q33346896 | Severe thrombocytopenic purpura due to rubella infection in a patient with systemic lupus erythematosus |
| Q47671088 | Sex, Symptom Severity, and Quality of Life in Rheumatology |
| Q33595036 | Simultaneous Occurrence of Deep Vein Thrombosis and Carotid Artery Thrombosis in Antiphospholipid Antibody Syndrome |
| Q37233852 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy |
| Q28199044 | Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies |
| Q54267466 | Splenic infarction: a rare cause of acute abdominal pain presenting in an older patient with primary antiphospholipid antibodies syndrome. |
| Q37961828 | Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome |
| Q90415373 | Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome |
| Q38874347 | Stroke During Norovirus Infection as the Initial Episode of Antiphospholipid Syndrome. |
| Q92737863 | Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome |
| Q32182200 | Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome Associated with MALT Lymphoma by Autologous Hematopoietic Stem Cell Transplantation |
| Q33380344 | Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up |
| Q51053159 | Superficial thrombophlebitis of the chest wall associated with anticardiolipin antibodies: antiphospholipid syndrome or Mondor's disease? |
| Q28217439 | Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy |
| Q30243901 | Systematic review of case reports of antiphospholipid syndrome following infection. |
| Q55282858 | Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. |
| Q52353641 | Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas. |
| Q45461798 | Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases |
| Q55933861 | Systemic lupus erythematosus |
| Q40439184 | Systemic lupus erythematosus : Unusual cutaneous manifestations |
| Q26741149 | Systemic lupus erythematosus: strategies to improve pregnancy outcomes |
| Q53159273 | Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. |
| Q33394044 | Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations |
| Q53189388 | The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. |
| Q59807283 | The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome |
| Q33385759 | The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe |
| Q64255347 | The IgA Isotype of Anti-β2 Glycoprotein I Antibodies Recognizes Epitopes in Domains 3, 4, and 5 That Are Located in a Lateral Zone of the Molecule (L-Shaped) |
| Q88399624 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository |
| Q39956194 | The Ped-APS Registry: the antiphospholipid syndrome in childhood |
| Q79870443 | The antiphospholipid syndrome |
| Q38873953 | The antiphospholipid syndrome: from pathophysiology to treatment. |
| Q35171977 | The antiphospholipid syndrome: multiple faces beyond the classical presentation |
| Q36928593 | The antiphospholipid syndrome: still an enigma |
| Q38680580 | The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex. |
| Q51814798 | The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V. |
| Q33419972 | The challenge of bleeding in antiphospholipid antibody-positive patients |
| Q43490656 | The challenge of pregnancy for patients with SLE. |
| Q98945626 | The clinical and laboratory manifestations profile of antiphospholipid syndrome among Saudi Arabia population: Examining the applicability of Sapporo criteria |
| Q24682842 | The clinical relevance of autoantibodies in scleroderma |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q24798707 | The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin |
| Q38125246 | The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus |
| Q48509173 | The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome |
| Q38570944 | The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome |
| Q36677026 | The environment and antiphospholipid syndrome |
| Q35140898 | The expanding spectrum of renal diseases associated with antiphospholipid syndrome |
| Q35172431 | The genetics of migraine |
| Q48005192 | The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome |
| Q37179099 | The impact of inherited thrombophilia on surgery: a factor to consider before transplantation? |
| Q45873735 | The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study |
| Q93020058 | The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS |
| Q33439904 | The role of platelets in antiphospholipid syndrome |
| Q33216930 | The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome |
| Q37738696 | The roll of Toll-like receptors in the antiphospholipid syndrome |
| Q33420910 | The significance and management of thrombocytopenia in antiphospholipid syndrome |
| Q87114991 | The spectrum between antiphospholipid syndrome and systemic lupus erythematosus |
| Q34560515 | The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review |
| Q33365607 | The systemic nature of the antiphospholipid syndrome |
| Q50248970 | The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. |
| Q33424085 | Therapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: A case report |
| Q28211977 | Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment |
| Q88930539 | Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment |
| Q33443797 | Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study |
| Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
| Q44338705 | Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India |
| Q33406643 | Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies |
| Q38497394 | Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies |
| Q38179334 | Tomography and blood vessels in Hughes syndrome. |
| Q28192395 | Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies |
| Q38063024 | Transverse myelitis |
| Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
| Q38755260 | Treatment of catastrophic antiphospholipid syndrome |
| Q34476952 | Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. |
| Q35308972 | Treatment of the antiphospholipid syndrome |
| Q33992907 | Treatment resistant severe digital ischemia associated with antiphospholipid syndrome in a male patient with systemic sclerosis |
| Q33348373 | Unusual manifestations of the antiphospholipid syndrome |
| Q38258585 | Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome |
| Q37738701 | Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome |
| Q38567072 | Vaccines, adjuvants and autoimmunity |
| Q35555909 | Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome |
| Q38086166 | Valvular heart disease in antiphospholipid syndrome |
| Q35680229 | Vascular and connective tissue diseases in the paediatric world |
| Q35189289 | Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis |
| Q38238048 | Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant |
| Q38951210 | What is known about pediatric antiphospholipid syndrome? |
| Q26825218 | What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions? |
| Q38013584 | When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). |
| Q79995141 | [Antiphospholipid antibodies and antiphospholipid syndrome: diagnosis and management] |
| Q78593780 | [Antiphospholipid antibodies evolving into connective tissue disease: follow-up study of women with recurrent misscarriage] |
| Q83009615 | [Antiphospholipid antibodies, antiphospholipid syndrome and suprarenal haematoma] |
| Q52927013 | [Antiphospholipid syndrome 2007. Current aspects of laboratory diagnostics and their therapeutic consequences]. |
| Q90416101 | [Antiphospholipid syndrome : Update on diagnostics and management] |
| Q79429271 | [Antiphospholipid syndrome] |
| Q87078561 | [Antiphospholipid syndrome] |
| Q87831212 | [Antiphospholipid syndrome] |
| Q84600564 | [Aquired inhibitors of coagulation in a patient with systemic lupus erythematosus and antiphospholipid antibodies: response to rituximab] |
| Q81153272 | [Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature] |
| Q84434376 | [Does cutaneous lupus erythematodes really exist?] |
| Q78658319 | [Nasal septal perforation and systemic disease] |
| Q80062138 | [Systemic lupus erythematosus] |
| Q41375519 | β2-Glycoprotein I-Dependent Anti-Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. |